Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Clinical trial NCT06132191 · APPROVED_FOR_MARKETING

Trial details

NCT number: NCT06132191
Sponsor: Regeneron Pharmaceuticals
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS

Non-Small Cell Lung Cancer (NSCLC)Basal Cell Carcinoma (BCC)Cutaneous Squamous Cell Carcinoma (CSCC)

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.